Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.
All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.
Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.
Intellia Therapeutics (NASDAQ:NTLA) has reported promising long-term Phase 1 data for nexiguran ziclumeran (nex-z) in treating hereditary ATTR amyloidosis with polyneuropathy. The single-dose treatment demonstrated sustained TTR reductions of at least 90% through three years, with significant clinical improvements.
Key findings include: 92% mean serum TTR reduction at 24 months in patients receiving ≥0.3 mg/kg doses (n=33), and 90% reduction at 36 months (n=12). Among 18 patients evaluated at 24 months, 72% showed clinically meaningful improvements in mNIS+7 scores. The treatment was generally well-tolerated, with only mild to moderate infusion-related reactions reported.
The company's Phase 3 MAGNITUDE-2 trial is progressing rapidly, with enrollment completion expected in H1 2026 and a potential BLA submission targeted for 2028.
Intellia Therapeutics (NASDAQ:NTLA) will present extended follow-up data from its Phase 1 trial of Nexiguran Ziclumeran (nex-z), a CRISPR-based gene editing therapy for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
The presentation will take place at the 5th International ATTR Amyloidosis Meeting on September 25, 2025 in Baveno, Italy. Dr. Julian Gillmore from the National Amyloidosis Centre will present efficacy and safety data including up to three years of patient follow-up and disease-relevant measures.
Intellia Therapeutics (NASDAQ:NTLA) has achieved a significant milestone by completing enrollment in its global Phase 3 HAELO study for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema (HAE). The study enrolled over 60 patients within nine months, with nearly half from the U.S.
The company expects to report topline data in H1 2026, followed by a BLA submission in H2 2026, targeting a U.S. launch in H1 2027. The HAELO study is a randomized, double-blind, placebo-controlled trial evaluating lonvo-z's efficacy in patients aged 16 and older with Type I or II HAE. Additional Phase 1/2 study data will be presented in Q4 2025.
Intellia Therapeutics (NASDAQ:NTLA) reported strong Q2 2025 results and significant progress in its clinical programs. The company ended Q2 with $630.5 million in cash, expecting to fund operations into H1 2027. Key highlights include accelerated enrollment in the Phase 3 MAGNITUDE trial for ATTR-CM, which will expand to approximately 1,200 patients, and the Phase 3 HAELO study for HAE completing randomization ahead of schedule.
The company presented compelling three-year follow-up data for lonvo-z in HAE, showing a 98% reduction in monthly attack rates. For nex-z in ATTR amyloidosis, Phase 1 data demonstrated strong TTR reduction in both wild-type and variant ATTR-CM patients. The company strengthened its commercial readiness with key leadership appointments and remains on track for BLA submission for lonvo-z in H2 2026.
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to five new employees under its 2024 Inducement Plan. The awards consist of 18,200 restricted stock units (RSUs) of Intellia's common stock.
The RSUs will vest in three equal installments on August 1 of 2026, 2027, and 2028, subject to continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has scheduled its second quarter 2025 earnings conference call for August 7, 2025, at 8:00 a.m. ET. The company will discuss financial results and operational highlights during the call.
Investors can access the call by dialing 1-833-316-0545 (U.S.) or 1-412-317-5726 (international). A live webcast will be available, and a replay will be accessible through Intellia's website after 12 p.m. ET on the same day.
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to six new employees under its 2024 Inducement Plan. The awards consist of 23,800 restricted stock units (RSUs) of Intellia's common stock.
The RSUs will vest in three equal installments on July 1 of 2026, 2027, and 2028, subject to continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4).
The treatment demonstrated 90% mean serum TTR reduction by Day 28 in patients receiving doses ≥0.3 mg/kg (n=33), with levels remaining stable for at least 24 months. Among 18 patients evaluated at 24 months, 14 showed clinically meaningful improvement of ≥4 points in mNIS+7 scores, including 5 of 6 patients previously progressing on patisiran.
The drug showed a favorable safety profile with only mild to moderate infusion-related reactions reported. The company continues enrollment in MAGNITUDE-2 trial, aiming for potential BLA submission by 2028.
FAQ
What is the current stock price of Intellia Therape (NTLA)?
What is the market cap of Intellia Therape (NTLA)?
